TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. During the last trading day the stock fluctuated 4. 89 $2. Stockhouse. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. The price has fallen in 5 of the last 10 days. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. When this page refreshes you will be logged in with the new address. A high-level overview of Theratechnologies Inc. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Cookies are used to offer you a better browsing experience and to analyze our traffic. GlobeNewswire. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. com uses cookies on this site. We also use them to share usage information with our partners. Theratechnologies, Inc. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Cookies are used to offer you a better browsing experience and to analyze our traffic. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. - Q3 2022 North American Revenue Growth of 19%. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The Company currently commercializes two products in the field of HIV. com uses cookies on this site. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. First Quarter Fiscal 2022 Financial Results. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. Who is Theratechnologies. MONTREAL, Oct. 22M. By continuing to use our service, you agree to our use of cookies. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. TH | October 13, 2022. 65 per cent to C$1. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. These pharmaceuticals. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Stockhouse. MONTREAL, Feb. Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. Cookies are used to offer you a better browsing. Losses were -47. Get the latest Sernova Corp (SVA) real. Headquarters. : 001-35203 Mr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. THERATECHNOLOGIES INC. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. Herein, we report. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. T. is a pharmaceutical company. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). 33 +0. GUD | Complete Knight Therapeutics Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. com uses cookies on this site. TH | May 19, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Montréal, Québec, Canada . Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. Stockhouse. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. MONTREAL, Feb. com. Stockhouse. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. : Renegotiated Lease to Generate Substantial Annual Savings. T. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Jours fériés des marchés. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 20% from a day low at $1. communications@theratech. (2013-04-03 | TSX:TH) Theratechnologies Inc. S. OTCQX – this is the premium tier of OTC stocks. US Headquarters. 4. Stockhouse. L. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 5% workforce reduction. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. T. . com. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. - Issued and outstanding common shares to be consolidated on the basis of 1 post. com uses cookies on this site. com uses cookies on this site. Stockhouse. 617-356-1009. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. This news release constitutes a “designated news release” for the purposes of the. Theratechnologies Stock Price, News and Company Updates. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Competitors: Unknown. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. By continuing to use our service, you agree to our use of cookies. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. MONTREAL, Dec. Agreement in principle on key amendments to loan. In the United States, Trogarzo ® (ibalizumab. com uses cookies on this site. . Stockhouse. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. 29(+0. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. 514-336-7800. 2% for this period. 39 50-Day Range $0. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (THTX) stock. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. S. Stockhouse. Theratechnologies Inc. Marsolais will present at the H. 16%. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the Company’s. com uses cookies on this site. Stockhouse. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. There are 102 news items for this page. ET. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. 38. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. Investor Relations. ir@theratech. Stockhouse. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Senior Director, Investor Relations. Investor Relations. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. . The company develops treatments for lipodystrophy . View recently published Stock News reports from independent reports and journalists. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 75. Browse posts by Sector and Subsector. com. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. Track Theratechnologies Inc. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. 0. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. 5000 0. $30. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. By Nick Paul Taylor Jul 12, 2023 8:57am. Gary Littlejohn. com uses cookies on this site. 1300 (+9. Theratechnologies Inc. $30. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The webinar will also address system-level barriers and present real-world. C. 00 in the next twelve months. Denis Boucher. View Company Info for Free. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. Cookies are used to offer you a better browsing experience and to analyze our traffic. 1-514-336-7800. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. 71. GlobeNewswire. Cookies are used to offer you a better browsing experience and to analyze our traffic. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Message Board Total Posts: 4. B2Gold Declares Fourth Quarter 2023 Dividend. 60%. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. TH | March 7, 2023. Free cash flow. Pour les émetteurs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. 2 million. Theratechnologies Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. com. acts as investment manager. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 40 f102M H1. com uses cookies on this site. T. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Sept. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Theratechnologies inc. is an employee of TaiMed Biologics USA, Inc. - 2023 Q3 positive adjusted EBITDA to be achieved. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Shares of Theratechnologies are up 4. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. $109. We also use them to share usage. View real-time stock prices and stock quotes for a full financial overview. 4. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. T. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. By continuing to use our service, you agree to our use of cookies. Stockhouse. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. T. Forecast to breakeven in 2024 Jul 15. See a list of the most recent Stock Forum posts on Stockhouse. By continuing to use our service, you agree to our use of cookies. 4 million. Learn why it. MONTREAL, Jan. 57%) Q1 2020 Earnings Call. Stockhouse. com uses cookies on this site. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Q3 2023 consolidated revenue of $20. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. H. com. (Image via Theralase Technologies Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This news release constitutes a “designated news release” for the purposes of the Company’s. Find the latest Theratechnologies Inc. lgibson. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. 06 million, an increase of 14. com uses cookies on this site. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. By continuing to use our service, you agree to our use of cookies. S. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. 67, which is an increase of 1,144. 03) EPS for the quarter, beating the consensus estimate of ($0. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. 5000 +0. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. We also use them to share usage. TH | February 28, 2023. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Vice President, Communications and Corporate Affairs. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. By continuing to use our service, you agree to our use of cookies. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Theratechnologies had a negative net margin of 36. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. (TH. com uses cookies on this site. Stockhouse. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. -based clinical sites participating in the conduct of the Phase. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Watch list NEW Set a price target alert After Hours Last. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. MONTREAL, Nov.